Literature DB >> 3665117

Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases.

E Martino1, F Aghini-Lombardi, S Mariotti, L Bartalena, M Lenziardi, C Ceccarelli, G Bambini, M Safran, L E Braverman, A Pinchera.   

Abstract

Amiodarone, an iodine-rich drug widely used for the treatment of cardiac tachyarrhythmias, may induce either hyperthyroidism or hypothyroidism. Of 467 patients chronically treated with this drug referred to our institution, amiodarone iodine-induced hypothyroidism (AIIH) developed in 28 patients (6%). AIIH patients were subdivided into two groups according to the presence (group A) or absence (group B) of underlying thyroid abnormalities. Thyroid autoantibodies were present in 10 of 19 patients from group A and 0 of 9 patients from group B. The thyroid 24-h radioiodine uptake (RAIU) was evaluated in 15 patients: low values (less than 4%) were found in three patients and detectable values (7-50%) were observed in 12. Perchlorate discharge tests were positive in all four patients tested. Follow-up data were available in 20 patients (16 in group A and four in group B). Hypothyroidism was transient in 12 (60%) and persistent for several months after amiodarone withdrawal in eight (40%). While all patients in group B had transient hypothyroidism, 50% of patients with underlying thyroid abnormalities (group A) had persistent hypothyroidism. Thyroid autoantibodies were found in seven of eight patients with persistent hypothyroidism and in only three of 12 patients with transient hypothyroidism. Conversely, seven of 10 patients with positive thyroid autoantibodies had persistent hypothyroidism and 9 of 10 patients with undetectable thyroid autoantibodies had transient hypothyroidism. These data indicate that: (i) AIIH may develop in patients with or without underlying thyroid abnormalities; (ii) RAIU is inappropriately elevated in many patients with AIIH; (iii) intrathyroidal iodine is not organified; (iv) serum thyroid autoantibodies represent a risk factor for the development of AIIH; (v) AIIH spontaneously remits after amiodarone withdrawal in patients without thyroid abnormalities, but may persist in patients with concomitant thyroid disorders, especially those with circulating thyroid autoantibodies.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3665117     DOI: 10.1111/j.1365-2265.1987.tb00781.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  20 in total

1.  Association between N-desethylamiodarone/amiodarone ratio and amiodarone-induced thyroid dysfunction.

Authors:  Mikie Yamato; Kyoichi Wada; Mai Fujimoto; Kouichi Hosomi; Tomohiro Hayashi; Akira Oita; Mitsutaka Takada
Journal:  Eur J Clin Pharmacol       Date:  2017-01-12       Impact factor: 2.953

2.  Suppression of thyroglobulin secretion in amiodarone iodine-induced thyrotoxicosis.

Authors:  M Weissel
Journal:  J Endocrinol Invest       Date:  1988-01       Impact factor: 4.256

3.  Association between Serum Amiodarone and N-Desethylamiodarone Concentrations and Development of Thyroid Dysfunction.

Authors:  Mikie Yamato; Kyoichi Wada; Tomohiro Hayashi; Mai Fujimoto; Kouichi Hosomi; Akira Oita; Mitsutaka Takada
Journal:  Clin Drug Investig       Date:  2018-01       Impact factor: 2.859

4.  Reversible hypothyroidism detected by normal 99mTc scan.

Authors:  M Coffernils; A Owen; J Unger
Journal:  Postgrad Med J       Date:  1989-12       Impact factor: 2.401

Review 5.  Amiodarone-induced thyroid disorders: a clinical review.

Authors:  K C Loh
Journal:  Postgrad Med J       Date:  2000-03       Impact factor: 2.401

Review 6.  Amiodarone and the thyroid: a 2012 update.

Authors:  F Bogazzi; L Tomisti; L Bartalena; F Aghini-Lombardi; E Martino
Journal:  J Endocrinol Invest       Date:  2012-03-19       Impact factor: 4.256

Review 7.  Drug-induced taste and smell disorders. Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction.

Authors:  R I Henkin
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

Review 8.  [Thyroid and treatment with amiodarone diagnosis, therapy and clinical management].

Authors:  Peter Mikosch
Journal:  Wien Med Wochenschr       Date:  2008

9.  Incidence and predictability of amiodarone-induced thyrotoxicosis and hypothyroidism.

Authors:  Andrea Hofmann; Clemens Nawara; Sedat Ofluoglu; Johannes Holzmannhofer; Bernhard Strohmer; Christian Pirich
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 10.  Effects of amiodarone therapy on thyroid function.

Authors:  Janna Cohen-Lehman; Peter Dahl; Sara Danzi; Irwin Klein
Journal:  Nat Rev Endocrinol       Date:  2010-01       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.